Skip To Main Content
Beit South Building on Muck Rack

Beit South Building

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Beit South

Contact Beit South, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Helen McShane and colleagues reply to Deborah Cohen

|
By Helen McShane, Adrian Hill, Mark Hatherill, Beit South Building
| bmj.com
Cohen questions the justification for a large efficacy trial of the novel tuberculosis (TB) vaccine MVA85A in South African infants.12 This trial confirmed that MVA85A was safe and provided valuable understanding of the TB vaccine.3 These trial results were published within 10 working days of our first seeing the data.24 We strongly agree with calls for rigor in conducting, and openness in reporting, preclinical studies, but we are confident that moving forward with this efficacy trial was...
Open in Who Shared Issue with article?
See all 1 articles